Search

Your search keyword '"Chronic respiratory tract disease"' showing total 13 results
Start Over Descriptor "Chronic respiratory tract disease"
13 results on '"Chronic respiratory tract disease"'

1. Urosepsis post emergency ureteric stent insertion: Can we predict intensive care admission?.

Author

Ong X.R., Manohar P., Martin C., Wetherell D., Ong X.R., Manohar P., Martin C., and Wetherell D.

Abstract

Introduction & Objectives: Urosepsis from ureteric obstruction is potentially life-threatening condition often requiring admission to intensive care unit (ICU). Gold standard care is emergency decompression with retrograde stenting or nephrostomy. Currently there is no universally accepted predictive tool to predict severity of urosepsis on admission. Our primary aim is to identify clinical factors that predict ICU admission post retrograde stenting. Our research goal is to ultimately develop a reproducible predictive algorithm for urosepsis severity. Material(s) and Method(s): A retrospective cohort study was performed in our institution from 2009 to 2019 of all patients who underwent emergency stent insertion. Data on patient demographics and medical history were extracted, specifically age, gender, weight, body mass index (BMI), diabetes mellitus, stroke, chronic respiratory disease, congestive cardiac failure, ischaemic heart disease, obstructive sleep apnoea, malignancy, immunosuppressive drugs and American Society of Anaesthesiologists (ASA) score. Systemic inflammatory response syndrome data including admission vital signs as well as serum haemoglobin, white cell count (WCC), neutrophils, creatinine, C-reactive protein and time to operation was also collected. Univariate and adjusted multivariate analysis was performed. The primary end point was ICU admission. Result(s): Overall 327 patients received emergency ureteric stent insertion. The mean age, and BMI were 61.3 years and 28.3 respectively. Rates of diabetes mellitus, malignancy and immunosuppressant drugs were 25.4%, 17.1%, 5.3% respectively. ASA score 3, 4, 5 were 42.5%, 11.3%, 0.9% respectively. A total of 75 (22.9%) patients were admitted to ICU post stent insertion. Univariate analysis found patients with ASA 4+5 combined were more likely than patients with ASA 1 to need ICU (OR= 4.5, 95% CI 1.31-15.46, p=0.02). Systolic blood pressure (95% CI 0.95-0.97, p=<0.001), diastolic blood pressure (95% CI 0

Published
2021

3. Animal and translational models of SARS-CoV-2 infection and COVID-19.

Author

McCaughan G.W., Rudloff I., Nold M.F., Hansbro N.G., Kim R.Y., Donovan C., Liu G., Faiz A., Short K.R., Lyons J.G., Tate M.D., Gorrell M.D., Cole A., Moreno C., Couteur D., Hesselson D., Triccas J., Neely G.G., Gamble J.R., Simpson S.J., Saunders B.M., Oliver B.G., Britton W.J., Wark P.A., Nold-Petry C.A., Hansbro P.M., Johansen M.D., Irving A., Montagutelli X., McCaughan G.W., Rudloff I., Nold M.F., Hansbro N.G., Kim R.Y., Donovan C., Liu G., Faiz A., Short K.R., Lyons J.G., Tate M.D., Gorrell M.D., Cole A., Moreno C., Couteur D., Hesselson D., Triccas J., Neely G.G., Gamble J.R., Simpson S.J., Saunders B.M., Oliver B.G., Britton W.J., Wark P.A., Nold-Petry C.A., Hansbro P.M., Johansen M.D., Irving A., and Montagutelli X.

Abstract

COVID-19 is causing a major once-in-a-century global pandemic. The scientific and clinical community is in a race to define and develop effective preventions and treatments. The major features of disease are described but clinical trials have been hampered by competing interests, small scale, lack of defined patient cohorts and defined readouts. What is needed now is head-to-head comparison of existing drugs, testing of safety including in the background of predisposing chronic diseases, and the development of new and targeted preventions and treatments. This is most efficiently achieved using representative animal models of primary infection including in the background of chronic disease with validation of findings in primary human cells and tissues. We explore and discuss the diverse animal, cell and tissue models that are being used and developed and collectively recapitulate many critical aspects of disease manifestation in humans to develop and test new preventions and treatments.Copyright © 2020, Society for Mucosal Immunology.

Published
2020

4. Educational topics and their rationale for inclusion within pulmonary rehabilitation - a systematic review.

Author

Lee A.L., Smith R., Osadnik C.R., Lee A.L., Smith R., and Osadnik C.R.

Abstract

Objective: To identify the scope of educational topics within pulmonary rehabilitation (PR) for people with chronic respiratory diseases and determine their rationale for inclusion. Method(s): Four electronic databases were searched, with data extracted and assessed for quality by two reviewers using the Downs and Black tool or the Critical Appraisal Skills Programme checklist. Result(s): Twenty-one studies of variable quality were included. In chronic obstructive pulmonary disease (COPD), common education topics included disease pathophysiology, medications, psychological support, strategies for breathlessness, role of exercise and recognition of acute exacerbations, while less frequent topics included end-of-life planning, disease impact on sexual relationships and comorbidities. In interstitial lung disease (ILD), topics focused upon disease pathophysiology, approaches to limit disease progression, symptom management and end-of-life care. Evidence of a rationale for including education topics in PR were often lacking, but focused on recommended guidelines and information to improve self-management. Conclusion(s): A core range of educational topics based broadly upon clinical presentation and management strategies appear to be incorporated into PR for people with COPD. Topics for people with ILD appear to be selected according to patient need. Practice Implications: The topics identified in this review may help clinicians seeking to develop educational resources for PR.Copyright © 2020 Elsevier B.V.

Published
2020

5. Fetal growth restriction (FGR) and respiratory morbidity in a very preterm birth cohort.

Author

Tan K., Sehgal A., Sehgal K., Tan K., Sehgal A., and Sehgal K.

Abstract

Background: Approximately 5-10% of infants delivered at term gestation have FGR, though, prevalence in preterm cohorts is not known. Preterm FGR infants may be at risk of greater morbidity. The objectives were to ascertain the prevalence of FGR amongst premature infants and to ascertain respiratory morbidity. Method(s): The institution database was accessed for all preterm infants between 24-31+6 weeks GA admitted to the NICU during the period 2014-2016 from data annually submitted to ANZNN. FGR was assigned postnatally as birthweight <10th centile for GA. FGR infants were compared with an equal number of consecutively born GA and gender matched AGA infants. Result(s): During the period, 973 infants between 24-32 weeks GA were admitted to the NICU. Of these, 206 (27%) were FGR. Between 28-32 weeks GA, approximately 1/3rd were FGR. GA and birthweight of the FGR and AGA cohorts were (30.2 +/- 0.2vs30.1 +/- 0.2 weeks, p = 0.8 & 1132 +/- 43vs1499 +/- 54 g, p < 0.0001). While administration of antenatal steroids, surfactant, mechanical ventilation, sepsis & PDA were comparable, the respiratory outcomes were significantly worse in the FGR cohort. This included duration of respiratory support (days), home oxygen n (%) and CLD ([37 +/- 10 vs. 23 +/- 5 days, p = 0.016], [24 (11.6%) vs. 8 (3.8%), p = 0.005] & [53 (25.7%) vs. 28 (13.6%), p = 0.002]), respectively. Conclusion(s): This data supports the 'fetal programming' hypothesis, whereby exposure to utero-placental insufficiency can result in alterations predisposing to chronic respiratory disease. As greater respiratory morbidity occurred while postnatal variables were comparable, management of FGR cohorts needs to be individualized.

Published
2019

6. Surgical aortic valve replacement versus trans-femoral aortic valve implantation using the lotus bio-prosthesis: Early and mid-term outcomes.

Author

Joshi P., Gooley R., Mccormick L., Smith J.A., Meredith I.T., Lo E.Y.W., Farag J., Shi W., Rashid H., Joshi P., Gooley R., Mccormick L., Smith J.A., Meredith I.T., Lo E.Y.W., Farag J., Shi W., and Rashid H.

Abstract

Introduction: Trans-catheter aortic valve implantation (TAVI) has emerged as a viable alternative to surgery for higher-risk patient subgroups. There are few reports from Australasia directly comparing early and mid-term outcomes between conventional surgical aortic valve replacement (AVR) and TAVI, especially with respect to the Lotus valve. We sought to do so by review of our centre's experience. Method(s): From 2012-2016, 125 patients underwent TAVI using the Lotus prosthesis at a single centre after assessment by a multidisciplinary heart valve team. These patients were compared to a historical control cohort of 184 patients undergoing isolated surgical AVR between 2000-2010 prior to the introduction of our TAVI program. Peri-operative characteristics were compared between groups as was mid-term survival and freedom from aortic regurgitation. Propensity-score matching was used for risk adjustment. Result(s): Patients undergoing TAVI were older (mean age, TAVI: 84 +/- 6 vs. AVR: 66 +/- 14, p < 0.001), and more likely to be female (55% vs. 37%, p = 0.002) and have chronic respiratory disease (23% vs. 145, p = 0.049). Unadjusted inhospital mortality was similar (TAVI: 2% vs. AVR: 5%, p = 0.25) as were rates of stroke (5% vs. 2%, p = 0.17). However, TAVI patients were more likely to experience post-procedure heart block requiring permanent pacemaker insertion (22% vs. 3%, p < 0.001). Propensity-score matching yielded 40 matched pairs. Amongst pairs, inhospital mortality was similar (3% vs. 10%, p = 0.36) as was stroke (5% vs. 5%, p > 0.99). There was a trend towards higher pacemaker rates in TAVI patients (15% vs. 3%, p = 0.06). Amongst matched pairs, survival at 3 years was similar (TAVI: 81% (71-97%) vs. AVR: 84% (7197%), p > 0.99). At 3 years, freedom from >= mild aortic regurgitation was comparable (77% (56-98%) vs. (70% (5486%), p = 0.48). None of the TAVI patients required a repeat aortic valve procedure while 2 AVR patients required re-do AVR. Conclusion(s)

Published
2017

7. Interactieve medische informatie van het huisartsen netwerk utrecht en de almere zorggroep

Subjects
Internet, prescription, validity, age distribution, diabetes mellitus, prevalence, article, incidence, medical information, chronic respiratory tract disease, Netherlands
Abstract

Introduction: Electronic medical record systems have great potential for monitoring and improving the quality of health services. In the Netherlands, GP-infonet (General Practitioner Information Network), a central medical information database, is available from 35 general practitioners (GPs) in Utrecht and 118 GPs in Almere. The database covers two patient populations: Utrecht with almost 58,000 persons and Almere with over 140,000 persons. These data can be retrieved interactively via the Web. Objective: We determined the incidence, prevalence, and prescription rates of several diagnoses in the two GP networks of GP-infonet. In addition, we estimated the extent to which these figures could be generalised for the whole of the Netherlands. Methods: Annual incidence and prevalence rates were calculated per 1000 person-years. Prescription rates were calculated for chronic respiratory diseases and diabetes mellitus in terms of the number of prescriptions per 100 episodes. These figures were compared with those from the Second Dutch National Survey of General Practice (2-DNSGP). The capacity of the data as far as generalisation is concerned was determined by comparing characteristics of the GPs and the patient population in Utrecht and Almere with the Dutch population using national figures. Results: Group practices and female GPs were over-represented in Utrecht and Almere. Distribution of age and gender in the patient population of Utrecht was similar to the Dutch population, while the population of Almere was relatively younger. Incidence and prevalence rates of Utrecht and Almere were comparable to 2-DNSGP, while prescription rates in Utrecht were somewhat higher than in 2-DNSGP. Prescription rates in Almere deviated from both Utrecht and 2-DNSGP. Conclusion: The information available on GP-infonet is representative - certainly as far as Utrecht is concerned - for the whole of the Netherlands and incidence and prevalence values are largely valid. However the registration and the processing of prescription rates in combination with diagnosis codes needs to be improved, especially in Almere. This could lead to the interactive data retrieval perhaps facilitating epidemiological studies and could further improve quality of registration and patient care in the network.

Published
2008

8. Interactieve medische informatie van het Huisartsen Netwerk Utrecht en de Almere Zorggroep

Author

Robert Veen, Annemiek Akkerman, Eelko Hak, Diederick E. Grobbee, Theo Verheij, and Methods in Medicines evaluation & Outcomes research

Subjects
Gerontology, validity, medicine.medical_specialty, age distribution, prevalence, Population, Prevalence, Medical information, Epidemiology, medicine, Medical prescription, education, Netherlands, Internet, prescription, education.field_of_study, business.industry, Incidence (epidemiology), article, Electronic medical record, medical information, Family medicine, diabetes mellitus, incidence, Diagnosis code, chronic respiratory tract disease, Family Practice, business
Abstract

Introduction: Electronic medical record systems have great potential for monitoring and improving the quality of health services. In the Netherlands, GP-infonet (General Practitioner Information Network), a central medical information database, is available from 35 general practitioners (GPs) in Utrecht and 118 GPs in Almere. The database covers two patient populations: Utrecht with almost 58,000 persons and Almere with over 140,000 persons. These data can be retrieved interactively via the Web. Objective: We determined the incidence, prevalence, and prescription rates of several diagnoses in the two GP networks of GP-infonet. In addition, we estimated the extent to which these figures could be generalised for the whole of the Netherlands. Methods: Annual incidence and prevalence rates were calculated per 1000 person-years. Prescription rates were calculated for chronic respiratory diseases and diabetes mellitus in terms of the number of prescriptions per 100 episodes. These figures were compared with those from the Second Dutch National Survey of General Practice (2-DNSGP). The capacity of the data as far as generalisation is concerned was determined by comparing characteristics of the GPs and the patient population in Utrecht and Almere with the Dutch population using national figures. Results: Group practices and female GPs were over-represented in Utrecht and Almere. Distribution of age and gender in the patient population of Utrecht was similar to the Dutch population, while the population of Almere was relatively younger. Incidence and prevalence rates of Utrecht and Almere were comparable to 2-DNSGP, while prescription rates in Utrecht were somewhat higher than in 2-DNSGP. Prescription rates in Almere deviated from both Utrecht and 2-DNSGP. Conclusion: The information available on GP-infonet is representative - certainly as far as Utrecht is concerned - for the whole of the Netherlands and incidence and prevalence values are largely valid. However the registration and the processing of prescription rates in combination with diagnosis codes needs to be improved, especially in Almere. This could lead to the interactive data retrieval perhaps facilitating epidemiological studies and could further improve quality of registration and patient care in the network.

Published
2008
Full Text
View/download PDF

9. Differential effects of temperature extremes on hospital admission rates for respiratory disease between indigenous and non-indigenous Australians in the Northern Territory

Author

Green, Donna, Bambrick, Hilary, Tait, Peter, Goldie, James, Schultz, Rosalie, Webb, Leanne, Alexander, Lisa, Pitman, Andy, Green, Donna, Bambrick, Hilary, Tait, Peter, Goldie, James, Schultz, Rosalie, Webb, Leanne, Alexander, Lisa, and Pitman, Andy

Abstract

The health gap between Indigenous and non-Indigenous Australians may be exacerbated by climate change if temperature extremes have disproportionate adverse effects on Indigenous people. To explore this issue, we analysed the effect of temperature extremes on hospital admissions for respiratory diseases, stratified by age, Indigenous status and sex, for people living in two different climates zones in the Northern Territory during the period 1993–2011. We examined admissions for both acute and chronic respiratory diagnoses, controlling for day of the week and seasonality variables. Our analysis showed that: (1) overall, Indigenous hospital admission rates far exceeded non-Indigenous admission rates for acute and chronic diagnoses, and Top End climate zone admission rates exceeded Central Australia climate zone admission rates; (2) extreme cold and hot temperatures were associated with inconsistent changes in admission rates for acute respiratory disease in Indigenous and non-Indigenous children and older adults; and (3) no response to cold or hot temperature extremes was found for chronic respiratory diagnoses. These findings support our two hypotheses, that extreme hot and cold temperatures have a different effect on hospitalisations for respiratory disease between Indigenous and non-Indigenous people, and that these health risks vary between the different climate zones. We did not, however, find that there were differing responses to temperature extremes in the two populations, suggesting that any increased vulnerability to climate change in the Indigenous population of the Northern Territory arises from an increased underlying risk to respiratory disease and an already greater existing health burden.

Published
2015

10. Integrated care pathways for airway diseases (AIRWAYS-ICPs)

Author

Bousquet, Jean, Addis, A., Adcock, I. M., Agache, I., Agusti, A., Alonso, A., Annesi-Maesano, I., Anto, Josep M., Bachert, C., Baena-Cagnani, C. E., Bai, C., Baigenzhin, A. K., Barbara, Cristina, Barnes, P. J., Bateman, E. D., Beck, L., Bedbrook, Anna, Bel, E. H., Benezet, O., Bennoor, K. S., Benson, M., Bernabeu-Wittel, M., Bewick, M., Bindslev-Jensen, C., Blain, Hubert, Blasi, F., Bonini, M., Bonini, S., Boulet, L. P., Bourdin, Arnaud, Bourret, Rodolphe, Brightling, C. E., Briggs, A. H., Brozek, J. L., Buhl, R., Bush, A., Caimmi, D. P., Calderon, M. A., Calverley, P. M., Camargos, P. A. M., Camuzat, Thierry, Canonica, G. W., Carlsen, K. H., Casale, T. B., Cazzola, M., A.M, Cepeda Sarabia, Cesario, A., Chen, Y. Z., Chkhartishvili, E., Chavannes, Niels H., Chiron, R., Chuchalin, Alexander G., Chung, K. F., Cox, L., Crooks, George, Cruz, A. A., Custovic, Adnan, Dahl, R., Dahlen, S. E., Blay, F. De, Dedeu, Antoni, Deleanu, D., Demoly, Pascal, Devillier, P., Didier, A., Dinh-Xuan, A. T., Djukanovic, R., Dokic, D., Douagui, H. B., Dubakiene, R., Eglin, S., Elliot, F., Emuzyte, R., Fabbri, Leonardo M., Fink-Wagner, A., Fletcher, M., Fokkens, W. J., Fonseca, J. A., Franco, A., Frith, P., Furber, A., Gaga, M., Garces, J., Garcia-Aymerich, Judith, Gamkrelidze, A., Diaz, S. González, Gouzi, Fares, Guzmán, M. A., Haahtela, T., Harrison, D., Hayot, M., Heaney, L. G., Heinrich, J., Hellings, P. W., Hooper, J., Humbert, M., Hyland, M. E., Iaccarino, G., Jakovenko, D., Jardim, J. R., Jeandel, Claude, Jenkins, C., Johnston, S. L., Jonquet, Olivier, Joos, G., Jung, K. S., Kalayci, O., Karunanithi, S., Keil, T., Khaltaev, N., Kolek, V., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Le, Tuyen D., Carlsen, K. C. Lodrup, Louis, R., MacNee, W., Mair, A., Majer, I., Manning, P. J., Keenoy, E. De Manuel, Masjedi, M. R., Melén, E., Gomes, Elisabete Melo, Menzies-Gow, A., Mercier, G., Mercier, Jacques, Michel, J. P., Miculinic, N., Mihaltan, F., Milenkovic, B., Molimard, M., Momas, I., Montilla-Santana, A., Almeida, M. Morais, Morgan, M., N'Diaye, M., Nafti, S., Nekam, K., Neou, A., Nicod, L., O'Hehir, R. E., Ohta, K., Paggiaro, P. L., Palkonen, S., Palmer, S., Papadopoulos, N. G., Papi, A., Passalacqua, G., Pavord, I., Pigearias, B., Plavec, D., Postma, D. S., Price, D., Rabe, K. F., Radier-Pontal, F., Redon, Josep, Rennard, S., Roberts, J., Robine, J. M., Roca, J., Roche, N., Rodenas, F., Roggeri, A., Rolland, C., Rosado-Pinto, J., Ryan, D., Samolinski, B., Sanchez-Borges, M., Schunemann, H. J., Sheikh, A., Shields, K. M., Siafakas, N., Sibille, Y., Similowski, T., Small, I., Sola-Morales, O., Sooronbaev, T., Stelmach, R., Sterk, P. J., Stiris, T., Sud, P., Tellier, V., To, T., Todo-Bom, A., Triggiani, M., Valenta, R., Valero, A. L., Valiulis, A., Valovirta, E., Ganse, E. Van, Vandenplas, O., Vasankari, T., Vestbo, J., Vezzani, G., Viegi, Giovanni, Visier, L., Vogelmeier, C., Vontetsianos, T., Wagstaff, R., Wahn, U., Wallaert, B., Whalley, B., Wickman, M., Williams, D. M., Wilson, N., Yawn, B. P., Yiallouros, Panayiotis K., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zhong, N., Zidarn, M., Zuberbier, T., Bousquet, J., Addis, A., Adcock, I., Agache, I., Agusti, A., Alonso, A., Annesi-Maesano, I., Anto, J. M., Bachert, C., Baena-Cagnani, C. E., Bai, C., Baigenzhin, A., Barbara, C., Barnes, P. J., Bateman, E. D., Beck, L., Bedbrook, A., Bel, E. H., Benezet, O., Bennoor, K. S., Benson, M., Bernabeu-Wittel, M., Bewick, M., Bindslev-Jensen, C., Blain, H., Blasi, F., Bonini, M., Bonini, S., Boulet, L. P., Bourdin, A., Bourret, R., Bousquet, P. J., Brightling, C. E., Briggs, A., Brozek, J., Buhl, R., Bush, A., Caimmi, D., Calderon, M., Calverley, P., Camargos, P. A., Camuzat, T., Canonica, G. W., Carlsen, K. H., Casale, T. B., Cazzola, M., Cepeda Sarabia, A. M., Cesario, A., Chen, Y. Z., Chkhartishvili, E., Chavannes, N. H., Chiron, R., Chuchalin, A., Chung, K. F., Cox, L., Crooks, G., Crooks, M. G., Cruz, A. A., Custovic, A., Dahl, R., Dahlen, S. E., De Blay, F., Dedeu, T., Deleanu, D., Demoly, P., Devillier, P., Didier, A., Dinh-Xuan, A. T., Djukanovic, R., Dokic, D., Douagui, H., Dubakiene, R., Eglin, S., Elliot, F., Emuzyte, R., Fabbri, L., Fink Wagner, A., Fletcher, M., Fokkens, W. J., Fonseca, J., Franco, A., Frith, P., Furber, A., Gaga, M., Garces, J., Garcia-Aymerich, J., Gamkrelidze, A., Gonzales-Diaz, S., Gouzi, F., Guzman, M. A., Haahtela, T., Harrison, D., Hayot, M., Heaney, L. G., Heinrich, J., Hellings, P. W., Hooper, J., Humbert, M., Hyland, M., Iaccarino, G., Jakovenko, D., Jardim, J. R., Jeandel, C., Jenkins, C., Johnston, S. L., Jonquet, O., Joos, G., Jung, K. S., Kalayci, O., Karunanithi, S., Keil, T., Khaltaev, N., Kolek, V., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Le, L. T., Lodrup Carlsen, K. C., Louis, R., Macnee, W., Mair, A., Majer, I., Manning, P., De Manuel Keenoy, E., Masjedi, M. R., Melen, E., Melo-Gomes, E., Menzies-Gow, A., Mercier, G., Mercier, J., Michel, J. P., Miculinic, N., Mihaltan, F., Milenkovic, B., Molimard, M., Momas, I., Montilla-Santana, A., Morais-Almeida, M., Morgan, M., N'Diaye, M., Nafti, S., Nekam, K., Neou, A., Nicod, L., O'Hehir, R., Ohta, K., Paggiaro, P., Palkonen, S., Palmer, S., Papadopoulos, N. G., Papi, A., Passalacqua, G., Pavord, I., Pigearias, B., Plavec, D., Postma, D. S., Price, D., Rabe, K. F., Radier Ponta, F., Redon, J., Rennard, S., Roberts, J., Robine, J. M., Roca, J., Roche, N., Rodenas, F., Roggeri, A., Rolland, C., Rosado-Pinto, J., Ryan, D., Samolinski, B., Sanchez-Borges, M., Schunemann, H. J., Sheikh, A., Shields, M., Siafakas, N., Sibille, Y., Similowski, T., Small, I., Sola-Morales, O., Sooronbaev, T., Stelmach, R., Sterk, P. J., Stiris, T., Sud, P., Tellier, V., To, T., Todo-Bom, A., Triggiani, M., Valenta, R., Valero, A. L., Valiulis, A., Valovirta, E., Van Ganse, E., Vandenplas, O., Vasankari, T., Vestbo, J., Vezzani, G., Viegi, G., Visier, L., Vogelmeier, C., Vontetsianos, T., Wagstaff, R., Wahn, U., Wallaert, B., Whalley, B., Wickman, M., Williams, D. M., Wilson, N., Yawn, B. P., Yiallouros, P. K., Yorgancioglu, A., Yusuf, O. M., Zar, H. J., Zhong, N., Zidarn, M., Zuberbier, T., Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Department of Allergy and Clinical Immunology, Faculty of Medicine-Transylvania University, Applied Tumor Virology, German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Ghent University Hospital, Laboratoire d'ingénierie osteo-articulaire et dentaire (LIOAD), Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), iQ4U consultants Ltd, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Department of Pathophysiology and Transplantation, Università degli Studi di Milano = University of Milan (UNIMI), Istituto di Geoscienze e Georisorse, Pavia, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] (LSCE), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Department of Infection, Immunity and Inflammation, Royal Brompton Hospital, Région Languedoc-Roussillon-Midi-Pyrénées, Service de physiologie et explorations fonctionelles [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University Hospital Southampton, Vilnius University [Vilnius], IMIM-Hospital del Mar, Generalitat de Catalunya, Helsingin yliopisto = Helsingfors universitet = University of Helsinki, University Hospitals Leuven [Leuven], University of Edinburgh, Pneumology Department, Marius Nasta Institute of Pneumology, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Monash University [Melbourne], Allergy and Respiratory Diseases, Università degli studi di Genova = University of Genoa (UniGe), Mécanismes moléculaires dans les démences neurodégénératives (MMDN), Université Montpellier 2 - Sciences et Techniques (UM2)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neurophysiologie Respiratoire Expérimentale et Clinique, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), AcademicMedical Center, Oslo University Hospital [Oslo], University of Coimbra [Portugal] (UC), Division of Clinical Immunology and Allergy, University of Naples Federico II = Università degli studi di Napoli Federico II, University of Turku, Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Consiglio nazionale delle ricerche, Instituto di fisiologia clinica, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Service de Pneumologie et Immuno-Allergologie [CHU LIlle], Pole Cardio-vasculaire et pulmonaire [CHU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), University Hospital of Cologne [Cologne], Çocuk Sağlığı ve Hastalıkları, AII - Amsterdam institute for Infection and Immunity, Pulmonology, Ear, Nose and Throat, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Milan, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), University of Helsinki, University of Genoa (UNIGE), Université de Montpellier (UM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL), Università degli studi di Napoli Federico II, Groningen Research Institute for Asthma and COPD (GRIAC), Yiallouros, Panayiotis K. [0000-0002-8339-9285], Custovic, Adnan [0000-0001-5218-7071], and Γιάλλουρος, Παναγιώτης

Subjects
Aging, Settore MED/10 - Malattie dell'Apparato Respiratorio, International Cooperation, Respiratory System, Medically Underserved Area, Comorbidity, Disease, Early intervention, Medical and Health Sciences, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Disease control, Risk Factors, Chronic obstructive lung disease, Health care, 030212 general & internal medicine, Rhiniti, media_common, Rhinitis, Environmental exposure, Child health care, 3. Good health, ALLERGIC RHINITIS, Europe, CHRONIC RESPIRATORY-DISEASES, PERFORMANCE PROGRAM, Action plan, SIMULATION, Asthma, Decision Making, European Union, Guidelines as Topic, Humans, Pulmonary Disease, Chronic Obstructive, Quality of Life, Respiration Disorders, World Health Organization, SMOKING, Human, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Chronic respiratory tract disease, DIAGNOSIS, OBSTRUCTIVE PULMONARY-DISEASE, 03 medical and health sciences, Quality of life (healthcare), EUROPEAN-UNION, medicine, MANAGEMENT, media_common.cataloged_instance, European union, Intensive care medicine, business.industry, Public health, Risk Factor, ta3121, Respiration Disorder, Integrated care, 030228 respiratory system, Physical therapy, Clinical Medicine, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, SEVERE ASTHMA
Abstract

International audience; The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYS-ICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers).

Published
2014
Full Text
View/download PDF

11. Feasibility intervention trial of two types of improved cookstoves in three resource-limited settings: study protocol for a randomized controlled trial

Author

Klasen, Elizabeth, Miranda, J. Jaime, Khatry, Subarna, Menya, Diana, Gilman, Robert Hugh, Tielsch, JamesM., Kennedy, Caitlin, Dreibelbis, Robert, Naithani, Neha, Kimaiyo, Sylvester, Chiang, Marilu, Carter, E.Jane, Sherman, Charles B., Breysse, Patrick N., Checkley, William, Huaman, A., Levano, M., Haustein, D., Rhodes, E., Grajeda, L., Levy, S., LeClerq, S., Wise, R., Mosol, P., Ogaro, F., Apaka, C., and Baliddawa, J.

Subjects
Lung Diseases, Research design, Health Knowledge, Attitudes, Practice, Time Factors, intervention study, spirometry, peak expiratory flow, environmental exposure, Indoor air pollution, Medicine (miscellaneous), Blood Pressure, Peak Expiratory Flow Rate, law.invention, Study Protocol, Behavior change, Randomized controlled trial, Risk Factors, law, Smoke, Biomass fuel, Forced Expiratory Volume, Peru, Ventilated cookstove, Medicine, Pharmacology (medical), Cooking, Intervention trial, Household Articles, Lung, adoption, Air Pollutants, Carbon Monoxide, Inhalation Exposure, Cross-Over Studies, Health Knowledge, article, feasibility study, Equipment Design, environmental change, Middle Aged, Improved cookstove, risk factor, Research Design, Exhalation, Air Pollution, Indoor, purl.org/pe-repo/ocde/ford#2.09.03 [https], Female, chronic respiratory tract disease, Environmental Monitoring, Adult, Developing country, self report, DLCO, Nepal, Environmental health, Adoption, Humans, Developing Countries, Disease burden, particulate matter, Protocol (science), Cultural Characteristics, biomass, business.industry, lung function, Kenya, mortality, household, semi structured interview, Spirometry, Housing, Feasibility Studies, business, Limited resources
Abstract

Background Exposure to biomass fuel smoke is one of the leading risk factors for disease burden worldwide. International campaigns are currently promoting the widespread adoption of improved cookstoves in resource-limited settings, yet little is known about the cultural and social barriers to successful improved cookstove adoption and how these barriers affect environmental exposures and health outcomes. Design We plan to conduct a one-year crossover, feasibility intervention trial in three resource-limited settings (Kenya, Nepal and Peru). We will enroll 40 to 46 female primary cooks aged 20 to 49 years in each site (total 120 to 138). Methods At baseline, we will collect information on sociodemographic characteristics and cooking practices, and measure respiratory health and blood pressure for all participating women. An initial observational period of four months while households use their traditional, open-fire design cookstoves will take place prior to randomization. All participants will then be randomized to receive one of two types of improved, ventilated cookstoves with a chimney: a commercially-constructed cookstove (Envirofit G3300/G3355) or a locally-constructed cookstove. After four months of observation, participants will crossover and receive the other improved cookstove design and be followed for another four months. During each of the three four-month study periods, we will collect monthly information on self-reported respiratory symptoms, cooking practices, compliance with cookstove use (intervention periods only), and measure peak expiratory flow, forced expiratory volume at 1 second, exhaled carbon monoxide and blood pressure. We will also measure pulmonary function testing in the women participants and 24-hour kitchen particulate matter and carbon monoxide levels at least once per period. Discussion Findings from this study will help us better understand the behavioral, biological, and environmental changes that occur with a cookstove intervention. If this trial indicates that reducing indoor air pollution is feasible and effective in resource-limited settings like Peru, Kenya and Nepal, trials and programs to modify the open burning of biomass fuels by installation of low-cost ventilated cookstoves could significantly reduce the burden of illness and death worldwide. Trial registration ClinicalTrials.gov NCT01686867

Published
2013
Full Text
View/download PDF

12. Falls and risk factors for falls in community-dwelling adults with dementia (NutriAlz Trial)

Author

Salvà A., Roqué M., Rojano X., Inzitari M., Andrieu S., Schiffrin E.J., Guigoz Y., and Vellas B.

Subjects
Male, Questionnaires, dysphagia, health status, functional status, Cohort Studies, Residence Characteristics, Risk Factors, psychologic test, Activities of Daily Living, parkinsonism, Randomized Controlled Trials as Topic, adult, falling, spasticity, cerebrovascular disease, aged, female, arthritis, nutritional assessment, priority journal, risk factor, depression, disease severity, Alzheimer disease, chronic respiratory tract disease, mental health, ADL disability, hypertension, review, visual disorder, weakness, Humans, controlled study, human, caregiver burden, daily life activity, major clinical study, body mass, joint prosthesis, Lewy body, Logistic Models, fracture, Spain, randomized controlled trial, Accidental Falls, Dementia, memantine, disease duration, Follow-Up Studies
Abstract

To estimate the number of fallers and risk factors for falls in a cohort with dementia, we did a secondary analysis of a cluster-randomized controlled trial (NutriAlz) in 11 outpatient and day care centers in Catalonia (Spain) including 626 community-dwelling patients with dementia, followed for 12 months. Participants' characteristics were assessed at baseline, at 6 and 12 months [fall in the earlier 6 mo, anthropometric data, comorbidities, Mini-Mental State Examination, Clinical Dementia Rating, Basic Activities of Daily Living (BADL), Instrumental Activities of Daily Living, Neuropsychiatric Inventory Questionnaire, Zarit Caregiver Burden Interview and Mini-Nutritional Assessment]. Multivariate logistic regression models and generalized linear models were used to explore risk factors for falls and changes in health and function. Two hundred twenty-three participants fell during the 12 months follow-up (35.62%). Risk factors identified for falls were age (odds ratio (OR)=1.03, 95% confidence interval (CI), 1.00-1.05), BADL (OR=1.18, 95% CI, 1.05-1.32), and earlier fall (OR=2.30, 95% CI, 1.57-3.35). Fallers had worse health than nonfallers, and their dependence increased significantly more in BADL during the study, compared with nonfallers. Dependence in BADL is a risk factor and a consequence of falls; interventions aimed at preventing falls in dementia patients could promote autonomy in BADL and slow its decline. Copyright © 2012 by Lippincott Williams & Wilkins.

Published
2012

13. Chronic diseases: the emerging pandemic.

Author

Terzic, Andre, Waldman, Scott A., Terzic, Andre, and Waldman, Scott A.

Abstract

According to the 2011 World Health Organization Global Status Report, of the 57 million annual global deaths – a staggering 36 million or over 63% are due to chronic diseases.1 Four noncommunicable diseases - namely cardiovascular, cancer, diabetes, and chronic respiratory diseases - emerge as the leading cause of mortality in the world, accounting respectively for 17, 7.6, 4.2, and 1.3 million deaths based on the latest available global epidemiology data. By 2020, global deaths due to chronic diseases are projected to worsen by at least 15 to 20%. It is estimated that the four major noncommunicable diseases will be responsible for 75% of worldwide deaths by 2030

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results